Covidien plc Announces 12-Month DEFINITIVE AR Results At VIVA 2014

LAS VEGAS--(BUSINESS WIRE)--Covidien plc (NYSE: COV) today announced 12-month results of the DEFINITIVE AR study, the first randomized study designed to identify the clinical benefits of plaque removal using directional atherectomy followed by drug coated balloon. The results were presented by Professor Thomas Zeller of the Universitaets-Herzzentrum, Bad Krozingen, Germany at the Vascular Interventional Advances (VIVA) 2014 conference in Las Vegas, Nev.

Help employers find you! Check out all the jobs and post your resume.